ChromaDex Appoints New CSO, Adds Director
Ticker: NAGE · Form: 8-K · Filed: Jun 25, 2024 · CIK: 1386570
| Field | Detail |
|---|---|
| Company | Chromadex Corp. (NAGE) |
| Form Type | 8-K |
| Filed Date | Jun 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $1,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-of-directors, personnel-change
Related Tickers: CDXC
TL;DR
ChromaDex names new CSO, adds a director to the board.
AI Summary
ChromaDex Corporation announced on June 19, 2024, the appointment of Dr. Robert Griffin as Chief Scientific Officer and the election of Ms. Sarah McSweeney to its Board of Directors. Dr. Griffin's appointment is effective immediately, and Ms. McSweeney's election is also effective as of June 19, 2024. The company also disclosed information regarding compensatory arrangements for certain officers.
Why It Matters
The appointment of a new Chief Scientific Officer and a new board member could signal strategic shifts or enhanced focus in research and development or corporate governance for ChromaDex.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and board changes, which are routine corporate governance events.
Key Players & Entities
- ChromaDex Corporation (company) — Registrant
- Dr. Robert Griffin (person) — Appointed Chief Scientific Officer
- Ms. Sarah McSweeney (person) — Elected to Board of Directors
- June 19, 2024 (date) — Effective date of appointments and election
FAQ
What is Dr. Robert Griffin's background and experience relevant to his new role as Chief Scientific Officer?
The filing does not provide specific details on Dr. Griffin's background or experience, only his appointment.
What specific expertise does Ms. Sarah McSweeney bring to the ChromaDex Board of Directors?
The filing does not detail the specific expertise Ms. McSweeney brings to the board.
Are there any changes to the compensation structure for existing officers mentioned in this filing?
The filing indicates that information regarding compensatory arrangements of certain officers is disclosed, but specific details are not provided within the provided text.
What is the primary focus of ChromaDex Corporation's scientific research and development?
The filing does not specify the primary focus of ChromaDex Corporation's scientific research and development.
What are the immediate priorities for the new Chief Scientific Officer, Dr. Robert Griffin?
The filing does not outline the immediate priorities for Dr. Robert Griffin in his new role.
Filing Stats: 575 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-06-25 17:18:41
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CDXC The Nasdaq Capital Mar
- $1,000 — Gerber will be paid a consulting fee of $1,000. The stock options and restricted stock
Filing Documents
- cdxc-20240619.htm (8-K) — 25KB
- letteragreementandconsulti.htm (EX-10.1) — 81KB
- image_0.jpg (GRAPHIC) — 8KB
- 0001628280-24-029936.txt ( ) — 258KB
- cdxc-20240619.xsd (EX-101.SCH) — 2KB
- cdxc-20240619_lab.xml (EX-101.LAB) — 21KB
- cdxc-20240619_pre.xml (EX-101.PRE) — 12KB
- cdxc-20240619_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 10.1 Letter Agreement and Consulting Agreement, dated as of June 25, 2024, by and between the Company and Brianna Gerber 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CHROMADEX CORPORATION Dated: June 25, 2024 By: /s/ Robert Fried Name: Robert Fried Chief Executive Officer